Predicting respiratory disorder mortality in dogs
Respiratory disorders in dogs can quickly become critical and are reported to be the second leading cause of cardiac arrest in canines. Therefore, it is necessary to take… read more.
Respiratory disorders in dogs can quickly become critical and are reported to be the second leading cause of cardiac arrest in canines. Therefore, it is necessary to take… read more.
Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to be beneficiaries, finds… read more.
Gilead Sciences Inc. announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to… read more.
In endometriosis, cells similar to uterine tissue grow outside the uterus. According to researchers in the Penn State Department of Kinesiology who study the disease, endometriosis is often… read more.
Nine out of 10 Australian teachers are experiencing severe stress, and nearly 70% say their workload is unmanageable, says UNSW Sydney research. A new study from researchers at… read more.
Madrigal Pharmaceuticals Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to… read more.
Ibuprofen and paracetamol are common over-the-counter medications that many of us reach for when we’re sick. But new research from the University of South Australia shows that these… read more.
Biogen Inc and Stoke Therapeutics Inc, a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, announced presentations of new clinical data… read more.
Ionis Pharmaceuticals,Inc. announced that the FDA has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age… read more.
The American Geriatrics Society (AGS) has released a landmark update to its list of alternatives to medications listed in the 2023 AGS Beers Criteria® — the most widely… read more.
Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29… read more.
BeOne Medicines Ltd. announced that the European Commission has approved a new film-coated tablet formulation of Brunkinsa (zanubrutinib) for all approved indications. “Developed to meet the real-world needs… read more.